In fact, as future directions, we plan to apply anti-IL-6 on PLum-AI cells and assess its effect as a sole treatment on PCa progression, or in combination with SB203580 and other traditional and in-clinical-trial PCa drugs, and further validate these findings using syngeneic in vivo mouse models. The gene discussed is IL6; the disease is posterior cortical atrophy.